Surmodics Company Profile (NASDAQ:SRDX)

About Surmodics (NASDAQ:SRDX)

Surmodics logoSurmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company's Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company's In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Adhesive
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:SRDX
  • CUSIP: 86887310
  • Web: www.surmodics.com
Capitalization:
  • Market Cap: $410.61 million
  • Outstanding Shares: 13,109,000
Average Prices:
  • 50 Day Moving Avg: $29.98
  • 200 Day Moving Avg: $26.30
  • 52 Week Range: $21.90 - $32.80
P/E:
  • Trailing P/E Ratio: 67.43
  • Foreward P/E Ratio: -1,031.67
  • P/E Growth: 10.00
Sales & Book Value:
  • Annual Revenue: $71.21 million
  • Price / Sales: 5.70
  • Book Value: $8.34 per share
  • Price / Book: 3.71
Profitability:
  • EBITDA: $15.57 million
  • Net Margins: 8.66%
  • Return on Equity: 7.28%
  • Return on Assets: 6.01%
Debt:
  • Current Ratio: 7.65%
  • Quick Ratio: 7.18%
Misc:
  • Average Volume: 35,260 shs.
  • Beta: 0.86
  • Short Ratio: 13.54
 

Frequently Asked Questions for Surmodics (NASDAQ:SRDX)

What is Surmodics' stock symbol?

Surmodics trades on the NASDAQ under the ticker symbol "SRDX."

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) posted its quarterly earnings data on Thursday, August, 3rd. The company reported $0.09 EPS for the quarter, topping the Zacks' consensus estimate of ($0.01) by $0.10. The company earned $17.80 million during the quarter, compared to the consensus estimate of $15.98 million. Surmodics had a net margin of 8.66% and a return on equity of 7.28%. The company's quarterly revenue was down 11.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.37 EPS. View Surmodics' Earnings History.

When will Surmodics make its next earnings announcement?

Surmodics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for Surmodics.

What guidance has Surmodics issued on next quarter's earnings?

Surmodics issued an update on its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $0.29-0.39 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.19. The company issued revenue guidance of $70.0-72.0, compared to the consensus revenue estimate of $67.59 million.

Where is Surmodics' stock going? Where will Surmodics' stock price be in 2017?

3 brokers have issued 12 month target prices for Surmodics' stock. Their forecasts range from $40.00 to $40.00. On average, they anticipate Surmodics' stock price to reach $40.00 in the next year. View Analyst Ratings for Surmodics.

Who are some of Surmodics' key competitors?

Who are Surmodics' key executives?

Surmodics' management team includes the folowing people:

  • Susan E. Knight, Independent Chairman of the Board
  • Gary R. Maharaj, President, Chief Executive Officer, Director
  • Andrew D. C. LaFrence, Vice President of Finance and Information Systems and Chief Financial Officer
  • Thomas A. Greaney, Executive Vice President of Medical Devices
  • Bryan K. Phillips, Senior Vice President - Legal and Human Resources, General Counsel & Secretary
  • Charles W. Olson, Senior Vice President of Commercial and Business Development, Medical Devices
  • Joseph J. Stich, Vice President, General Manager - In Vitro Diagnostics
  • Timothy J. Arens, Vice President - Corporate Development and Strategy
  • Gregg S. Sutton, Vice President - Research & Development
  • Lisa Wipperman Heine, Director

How do I buy Surmodics stock?

Shares of Surmodics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Surmodics' stock price today?

One share of Surmodics stock can currently be purchased for approximately $30.95.


MarketBeat Community Rating for Surmodics (NASDAQ SRDX)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  212
MarketBeat's community ratings are surveys of what our community members think about Surmodics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Surmodics (NASDAQ:SRDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $40.00 (29.24% upside)
Consensus Price Target History for Surmodics (NASDAQ:SRDX)
Price Target History for Surmodics (NASDAQ:SRDX)
Analysts' Ratings History for Surmodics (NASDAQ:SRDX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/14/2017Lake Street CapitalInitiated CoverageBuy -> Buy$40.00MediumView Rating Details
6/27/2017AegisInitiated CoverageBuyHighView Rating Details
11/21/2016Barrington ResearchDowngradeOutperform -> Market PerformN/AView Rating Details
10/6/2016SidotiDowngradeBuy -> Neutral$33.00N/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Surmodics (NASDAQ:SRDX)
Earnings by Quarter for Surmodics (NASDAQ:SRDX)
Earnings History by Quarter for Surmodics (NASDAQ SRDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017($0.01)N/AView Earnings Details
8/3/2017Q3 2017($0.01)$0.09$15.98 million$17.80 millionViewListenView Earnings Details
4/27/2017Q2 2017$0.07$0.05$16.21 million$17.50 millionViewN/AView Earnings Details
2/2/2017Q117$0.09$0.19$15.81 million$17.80 millionViewListenView Earnings Details
11/16/2016Q4 2016$0.09$0.26$16.09 million$18.20 millionViewListenView Earnings Details
7/28/2016Q316$0.12$0.37$16.31 million$19.97 millionViewListenView Earnings Details
5/2/2016Q2$0.09$0.20$14.71 million$16.70 millionViewListenView Earnings Details
1/28/2016Q116$0.17$0.38$14.58 million$16.50 millionViewListenView Earnings Details
11/10/2015Q415$0.19$0.30$15.30 million$17.40 millionViewListenView Earnings Details
8/5/2015Q315$0.21$0.26$14.86 million$15.90 millionViewListenView Earnings Details
4/30/2015Q2$0.20$0.19$14.09 million$14.40 millionViewListenView Earnings Details
1/29/2015Q414$0.21$0.25$14.30 million$14.20 millionViewListenView Earnings Details
11/6/2014Q314$0.25$0.26$14.90 million$15.30 millionViewN/AView Earnings Details
7/31/2014Q214$0.23$0.27$14.84 million$14.62 millionViewListenView Earnings Details
5/1/2014Q114$0.20$0.22$14.40 million$13.60 millionViewListenView Earnings Details
1/30/2014Q413$0.21$0.21$14.15 million$13.90 millionViewListenView Earnings Details
11/5/2013Q313$0.22$0.26$14.32 million$14.30 millionViewListenView Earnings Details
7/31/2013Q3 2013$0.21$0.22$15.03 million$14.29 millionViewListenView Earnings Details
5/7/2013Q2 2013$0.21$0.20$13.92 million$13.70 millionViewListenView Earnings Details
1/30/2013Q1 2013$0.18$0.29$13.63 million$13.85 millionViewListenView Earnings Details
11/6/2012Q412$0.17$0.17$13.83 million$13.80 millionViewN/AView Earnings Details
8/1/2012$0.14$0.17ViewN/AView Earnings Details
5/8/2012$0.15$0.14ViewN/AView Earnings Details
11/3/2011$0.05$0.06ViewN/AView Earnings Details
8/3/2011$0.04$0.13ViewN/AView Earnings Details
4/27/2011$0.08ViewN/AView Earnings Details
1/26/2011$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Surmodics (NASDAQ:SRDX)
2017 EPS Consensus Estimate: $0.18
2018 EPS Consensus Estimate: $0.20
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.05$0.12$0.09
Q2 20172$0.05$0.08$0.07
Q3 20172$0.00$0.03$0.02
Q4 20172($0.01)$0.04$0.02
Q1 20181$0.01$0.01$0.01
Q2 20181$0.06$0.06$0.06
Q3 20181$0.06$0.06$0.06
Q4 20181$0.07$0.07$0.07
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Surmodics (NASDAQ:SRDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Surmodics (NASDAQ:SRDX)
Insider Ownership Percentage: 6.40%
Institutional Ownership Percentage: 84.85%
Insider Trades by Quarter for Surmodics (NASDAQ:SRDX)
Institutional Ownership by Quarter for Surmodics (NASDAQ:SRDX)
Insider Trades by Quarter for Surmodics (NASDAQ:SRDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Charles W OlsonVPSell801$27.85$22,307.85View SEC Filing  
9/11/2017Joseph J. StichVPSell1,000$27.28$27,280.00View SEC Filing  
8/7/2017Gary R MaharajCEOSell5,000$25.75$128,750.00View SEC Filing  
7/3/2017Gary R MaharajCEOSell5,000$28.03$140,150.00View SEC Filing  
6/16/2017Bryan K PhillipsSVPSell1,226$24.85$30,466.10View SEC Filing  
6/9/2017Joseph J StichVPSell1,000$25.31$25,310.00View SEC Filing  
6/5/2017Gary R MaharajCEOSell2,702$25.09$67,793.18View SEC Filing  
4/3/2017Gary R. MaharajCEOSell584$25.00$14,600.00View SEC Filing  
3/6/2017Joseph J. StichVPSell1,000$24.73$24,730.00View SEC Filing  
12/22/2016Charles W OlsonVPSell1,201$26.00$31,226.00View SEC Filing  
12/8/2016Charles W OlsonVPSell3,699$26.02$96,247.98View SEC Filing  
12/5/2016Joseph J StichVPSell1,000$23.97$23,970.00View SEC Filing  
12/2/2016Bryan K PhillipsSVPSell1,264$23.90$30,209.60View SEC Filing  
11/25/2016Charles W OlsonVPSell500$26.02$13,010.00View SEC Filing  
11/7/2016Gary R MaharajCEOSell5,000$25.22$126,100.00View SEC Filing  
10/3/2016Gary R. MaharajCEOSell5,000$29.55$147,750.00View SEC Filing  
8/17/2016Charles W OlsonVPSell9,936$28.98$287,945.28View SEC Filing  
8/15/2016Susan E. KnightDirectorSell1,548$28.64$44,334.72View SEC Filing  
8/1/2016Charles W OlsonVPSell12,500$27.08$338,500.00View SEC Filing  
6/14/2016Bryan K PhillipsSVPSell1,816$23.44$42,567.04View SEC Filing  
6/10/2016Joseph J StichVPSell1,000$23.33$23,330.00View SEC Filing  
5/27/2016Susan E KnightDirectorSell1,001$22.71$22,732.71View SEC Filing  
3/4/2016Timothy J ArensVPSell10,291$18.43$189,663.13View SEC Filing  
12/4/2015Joseph J StichVPSell1,000$21.18$21,180.00View SEC Filing  
9/4/2015Joseph J StichVPSell1,000$23.57$23,570.00View SEC Filing  
6/5/2015Joseph J StichVPSell1,000$23.84$23,840.00View SEC Filing  
5/22/2015Bryan K PhillipsSVPSell7,293$25.25$184,148.25View SEC Filing  
12/29/2014Charles W OlsonVPSell5,083$21.98$111,724.34View SEC Filing  
12/8/2014Charles W OlsonVPSell3,365$21.66$72,885.90View SEC Filing  
11/19/2014Timothy J ArensVPSell10,330$21.02$217,136.60View SEC Filing  
5/8/2014Susan KnightDirectorBuy1,500$20.36$30,540.00View SEC Filing  
12/4/2013Bryan PhillipsSVPSell16,236$22.95$372,616.20View SEC Filing  
5/15/2013Mark A LehmanInsiderSell1,693$26.55$44,949.15View SEC Filing  
8/10/2012Value Lp StarboardMajor ShareholderSell257,560$17.74$4,569,114.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Surmodics (NASDAQ:SRDX)
Latest Headlines for Surmodics (NASDAQ:SRDX)
Source:
Loading headlines, please wait.

Social

Chart

Surmodics (SRDX) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.